Access Bio said on Tuesday that it secured a new equity stake in CuraPatients, a U.S. digital population health-based company, to accelerate its entry into the American digital healthcare sector.
Access Bio is a Kosdaq-listed U.S. company developing next-generation diagnostic kits in which Korean pharmaceutical, PharmaGen Science, has acquired a majority stake.
Meanwhile, CuraPatients is a California-based company with an artificial intelligence (AI)-based software-as-a-service (SaaS) solution, which is Federal Risk and Authorization Management Program (FedRAMP) certified. The certification provides a standardized approach to security assessment, certification, and continuous monitoring of cloud products and services.
According to CuraPatient, this certification gives it access to patient information from every agency within the U.S. federal government and a competitive advantage in the U.S. public sector digital healthcare services space. CuraPatient also provides vaccination and chronic disease appointment management services to some of the largest pharmacy chains in the U.S. so that the private sector can leverage its business network.
Additionally, CuraPatient has a healthcare platform that can manage medical service scheduling using ChatGPT and optimize the utilization of medical personnel in hospitals, and medical appointment services through a mobile application called, “Othena.”
Access Bio, which has a wide range of diagnostic products, has set a common goal to maximize synergies through collaboration between both companies.
Accordingly, Access Bio plans to first utilize CuraPatient's reservation application as a new distribution channel to sell and supply its products. The company also expects to collaborate with CuraPatient to build a one-stop integrated solution platform for prevention, diagnosis, prescription, and treatment, in the future.
"CuraPatient's high level of security technology, digital healthcare service platform that can connect patients, doctors and hospitals, and business network in the U.S. will be a solid foundation for our digital healthcare business expansion,” said an Access Bio official. "We will continue to accelerate our entry into the digital healthcare business through strategic partnerships with various companies."